Form 4: Nurix Therapeutics Director Roy D. Baynes Acquires 25,000 Stock Options
SEC Form 4 Filing
Director Roy D. Baynes acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 19, 2025.
Summary
- Roy D. Baynes, a director of Nurix Therapeutics, Inc., acquired 25,000 stock options on May 19, 2025.
- The options have an exercise price of $9.51.
- The options vest fully on the earlier of the next annual meeting of the Issuer's stockholders or May 19, 2026, contingent on continued service to the Issuer.
- The expiration date for the options is May 18, 2035.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction without expressing any positive or negative outlook.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor their investment decisions.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence, as it indicates that a director is investing in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of transaction: Roy D. Baynes acquired 25,000 stock options. |
| 05/19/2025 | Date of filing. |
| 05/19/2026 | Vesting date of the stock options, contingent on continued service (or earlier if the next annual meeting occurs before this date). |
| 05/18/2035 | Expiration date of the stock options. |
Keywords
stock options, Form 4, Nurix Therapeutics, NRIX, insider trading, beneficial ownership, Roy D. Baynes, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.